Kornimate/medical-research-clean huggingface dataset:
electronic cigarettes as a harm reduction strategy in individuals with substance use disorder

Conditions: Cigarette Smoking; Addiction; E Cig Use

Summary: patients in addiction treatment have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. the purpose of this study is to examine the feasibility of using e-cigarettes as a method for harm reduction and the effects of providing e-cigarettes (or placebo e-cigarettes) on smoking outcomes among patients in addiction treatment.

electronic nicotine delivery devices often referred to as e-cigarettes, are battery-powered devices that deliver vaporized nicotine when inhaled. corresponding with the growth in media attention, marketing and promotion, awareness and use of e-cigarettes has increased dramatically. a large proportion of those using e-cigarettes use them to reduce the number of cigarettes they are smoking or to help them quit. use of an e-cigarette by smokers unwilling or unable to stop smoking completely might be a good approach to reducing cigarette consumption as the e-cigarette imitates some behavioral aspects of cigarette smoking and contains nicotine. moreover, the few existing studies on the effect of e-cigarettes on tobacco withdrawal and craving suggest promising potential to assist smokers in coping with smoking urges and decreasing cigarette use.

Eligibility criteria:
inclusion criteria: * smokes at least 10 cigarettes per day * meet dsm-v aud and/or oud within the past year, interested in reducing cpds * able to provide consent * use a cell phone, are willing/able to receive and respond to daily text messages regarding their cigarette use and e-cigarette use on their cell phone * provide one additional contact, and are willing to use an e-cigarette for 3 weeks. exclusion criteria: * pregnant and/or breast feeding (self-reported) * currently using smoking cessation medications (including other forms of nrt, buproprion, or varenicline) * enrolled in a smoking cessation program or another cessation tria * have used an e-cigarette in the past 14 days * have used any other tobacco products (pipe, cigar, cigarillos, snuff, chewing tobacco, rolling tobacco, or hookah/shisha) in the past 30 days * report having a history of asthma, other airways diseases, or heart disease.
community-based cognitive therapy for suicide attempters

Conditions: Suicide, Attempted

Summary: this study will determine the effectiveness of cognitive behavioral therapy (cbt) in preventing future suicide attempts in repeat suicide attempters.

rates of mental health and substance use disorders are high among economically disadvantaged, ethnic minority populations. studies have shown that cbt designed for this high-risk population is successful at reducing suicide attempts in people with suicidal thoughts or attempts. this study will implement a cbt intervention into the community and will focus on increasing compliance with psychiatric, substance abuse, and medical treatment. participants in this study will be randomly assigned to receive either cbt plus standard care or standard care alone. participants who receive cbt will have ten weekly sessions of treatment. suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed. assessments will be made 1, 3, 6, 12, 18, and 24 months after study completion.

Eligibility criteria:
inclusion criteria: * suicide attempt within 48 hours prior to being evaluated at the hospital * english speaking * able to provide 2 verifiable contacts exclusion criteria: * acute, unstable, or severe axis iii disorder or a severe axis i disorder that may prevent safe participation in outpatient psychotherapy

Keywords: minority groups
evaluation of iprf with vitamin c in stageii grade a periodontitis

Conditions: Periodontitis

Summary: comparing the effect of using vitamin c with injectable prf as a locally delivered adjunct to scaling and root planing versus scaling and root planing with local delivery of injectable prf and scaling and root planing alone on the clinical parameters in stage ii grade a periodontitis patients.

the conventional approach: group 1: scaling and root planing alone using gracey curettes and ultrasonic scalers. group 2: scaling and root planing using gracey curettes and ultrasonic scalers with local delivery of injectable prf using an insulin syringe with the blunt needle inserted into the bottom of the periodontal pocket through a template to hold the locally delivered injectable prf. the intervention approach: scaling and root planing using gracey curettes and ultrasonic scalers with local delivery of vitamin c (250 μm) and injectable prf, using an insulin syringe with the blunt needle inserted into the bottom of the periodontal pocket through a template to hold the locally delivered vitamin c and injectable prf for a longer time.

Eligibility criteria:
inclusion criteria: 1. patients with healthy systemic condition. 2. adult patients ˃ 18 years old. 3. patients with stage ii grade a periodontitis. 4. patients accept 6-months follow-up period (cooperative patients). 5. patients provide an informed consent. exclusion criteria: 1. presence of prosthetic crowns. 2. extensive restorations. 3. periodontal therapy within the last 12 months. 4. having surgical therapy or undergoing orthodontic treatment. 5. ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis. 6. the use of antibiotics or anti-inflammatory drugs 1 month prior to the procedure and till the end of 6 months of follow-up. 7. smokers. 8. pregnant females.
the effects of rvx000222 on glucose metabolism in individuals with pre-diabetes

Conditions: Diabetes

Summary: this study builds on data that high-density lipoprotein (hdl) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. the primary objective of this study is to determine the effects of rvx000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (ifg) or impaired glucose tolerance (igt), during a frequently sampled oral glucose tolerance test (ogtt).


Eligibility criteria:
inclusion criteria: * males aged 18-70 years, inclusive * body mass index (bmi): 25-40 kg/m2 * hdl cholesterol plasma levels: ≤1.4 mmol/l * pre-diabetes: either impaired fasting glucose (ifg; 6.1-6.9mmol/l) or impaired glucose tolerance (igt; 2 hour ogtt glucose 7.8-11.0mmol/l, who classification) as measured at visit 1 * no current use or need for prescription or over-the-counter medication within four days of visit 1 * have given signed informed consent to participate in the study exclusion criteria: * identification of any other medical condition requiring immediate therapeutic intervention * has received any over-the-counter medication including vitamins, herbal, or dietary supplements within four days of visit 1 unless prior approval from the investigator * tobacco use within six months of visit 1 (including cigarettes, pipes, chewing tobacco) * elective surgery requiring general anaesthesia during the course of the study * clinically significant heart disease at visit 1 * clinically significant abnormal ecg at visit 1 * evidence of renal impairment defined as serum creatinine \>1.5 mg/dl (133 μmol/l) or creatinine clearance of \<60 ml/min * history of hypertension or supine sbp \>160mmhg or dbp \>95mmhg as measured at visit 1 * evidence of type 2 diabetes (fasting plasma glucose ≥7.0mmol/l; 2 hour ogtt glucose ≥11.1mmol/l) * evidence of liver disease defined as aspartate aminotransferase (ast), alanine aminotransferase (alt) or total bilirubin \>1.5 x upper limit of normal (uln) at visit 1 * history of malignancy within past 5 years * history or evidence of drug or alcohol abuse within 12 months of visit 1 * use of other investigational drugs and/or devices at the time of enrolment, or within 30 days of visit 1 * history of non-compliance to medical regimens or unwillingness to comply with the study protocol * any condition that in the opinion of the investigators would confound the evaluation and interpretation of the data * persons directly involved in the execution of the protocol
transforming ed throughput with ai-driven clinical decision support system

Conditions: Critical Care; Emergency Treatment; Triage; Readmission

Summary: the aims of this study is to integrate real-time data flow infrastructure between hospital information system and ai models and to conduct a cluster randomized crossover trial to evaluate the efficacy of the ai models in improving patient flow and relieving ed crowding.


Eligibility criteria:
inclusion criteria: * ed patients aged 20 years or older * patients were treated by the recruited 16 ed attendings. exclusion criteria: * patients aged less than 20 years. * patients were not treated by the recruited 16 ed attendings.

Keywords: critical care emergency treatment triage readmission
a study of lp-128 capsules in healthy subjects

Conditions: Chronic Hepatitis b

Summary: a randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and pharmacokinetics of lp-128 capsules after single- and multiple-dose in healthy subjects

this trial includes single dose and multiple dose phases. the single-dose phase included six dose cohorts. based on the safety and pharmacokinetic results of single-dose study, approximately 2 doses will be selected to conduct multiple-dose study. the primary study objectives are to evaluate the safety, tolerability, and pharmacokinetic characteristics of lp-128 capsules in healthy subjects after single and multiple dosing.

Eligibility criteria:
inclusion criteria: * subjects have no history of serious digestive system, central nervous system, cardiovascular system, kidney, respiratory system, metabolism and endocrine, skeletal and muscular system, blood system disease and cancer * subjects (including partners) are willing to take effective contraception measures during study and within 3 months after last dose * male and female healthy subjects aged 18 to 55 years old * male subjects weigh ≥ 50 kg, and female subjects weigh ≥ 45 kg * subjects able to understand and comply with study requirements * willing to sign the informed consent and fully understand the content, process and possible adverse reactions of the trial exclusion criteria: * abnormal vital signs, physical examination or laboratory tests with clinical significance * abnormal ecg, chest x-ray, abdominal ultrasound or echocardiography with clinical significance * positive screening for viral hepatitis, hiv and syphilis * subjects who have taken any drugs or health care products within 14 or 28 days before administration the study drug; or subjects who have consumed tea or alcohol-containing food product within 24hrs before administration the study drug * subjects who have a history of dysphagia or condition may affect drug absorption, distribution, metabolism and excretion * female subjects are breastfeeding or pregnant * subjects who have a history of drug/alcohol/tobacco abuse * subjects who have had a blood donation or massive blood loss within three months before screening; or had major surgery within six months before screening * subjects who have participated in other clinical trial within three months before screening * subjects have special dietary requirements or cannot tolerate a standard meal * subjects who are not suitable for this trial based on the assessment of investigator
a study to assess safety, tolerability and pk of azd2171 and chemotherapy on patients with solid tumors

Conditions: Advanced Solid Tumor

Summary: a multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of azd2171 when administered with various anticancer regimens (part a) and to confirm the tolerability of its combination with folfox (part b).


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic cancer that is not amenable to surgery or radiation therapy with curative intent * measurable lesion by ct or other techniques according to recist exclusion criteria: * inadequate bone marrow reserve * history of poorly controlled hypertension

Keywords: advanced solid tumors azd2171 phase i
a comparison of the pacemaker automatic features in reduction of ventricular pacing

Conditions: Bradycardia

Summary: the compare-adapta study is a randomized, multi-center, prospective study conducted in china. the purpose of the study is to compare the ability of search av™+ and managed ventricular pacing® (mvp®) to reduce ventricular pacing in dual chamber pacemaker-indicated patients. the compare-adapta study will also observe atrial fibrillation (af) burden as demonstrated by cardiac compass® and the clinical profile adapta® pacemaker patients.

recent studies suggest that chronic right ventricular pacing is associated with a variety of adverse effects in patients, particularly those with intact or intermittent atrioventricular (av) conduction. medtronic adapta® pacemakers include managed ventricular pacing®, a pacing mode designed to promote intrinsic conduction, and also search av™+, a feature designed to reduce unnecessary ventricular pacing in patients with intact or intermittent av conduction.

Eligibility criteria:
inclusion criteria: * signed and dated study informed consent * class i or class iia pacemaker indication * geographically stable and available for follow-up at the center for the length of the study * age greater than 18 * to be implanted with adapta dual chamber pacemaker exclusion criteria: * unwillingness or inability to give written informed consent to participate in the study * patient with a previously implanted pacemaker/implantable cardioverter-defibrillator (icd)/cardiac resynchronization therapy (crt) device * life expectancy of less than one year * patient has a mechanical tricuspid heart valve * medical conditions that preclude the testing requirement by the protocol or limit study participation * patient has persistent 3rd degree atrioventricular (av) block * patient has persistent atrial fibrillation (af) * patient has neurogenic syncope * patient has carotid sinus syndrome * patient has hypertrophic obstructive cardiomyopathy * inclusion in another clinical trial or study

Keywords: managed ventricular pacing
anger and psychotrauma: data from military and civilians

Conditions: Post-traumatic Stress Disorder

Summary: post-traumatic stress disorder (ptsd) is mainly associated with several emotions such as anger, guilt or shame. by interfering with psychotherapeutic work these emotions can be problematic. when suffering from ptsd, pervasive anger can also have relational consequences. anger and ptsd are mutually reinforcing: anger can aggravate ptsd symptoms and aggressive behaviours, and conversely, ptsd promotes high levels of anger and aggression. a few explanatory hypotheses have been proposed. in terms of personality factors, anger-treatment may promote the severity of ptsd symptoms and the development of aggressive behaviours. in terms of stressors, exposure to combat and combat-related moral harms could play a role in the relationship between ptsd, anger and traumatic experiences over the course of life. finally, in clinical terms, in the presence of ptsd, anger and aggressive behaviours may be triggered by substance abuse and depression. within the anglo-saxon literature, it is recognized that both civilians and military personnel with ptsd exhibit high levels of anger, with a possible predominance among military personnel. while we know that anger management mechanisms can be strongly influenced by cultural aspects and the type of event, there is no data in the french population. this study proposes to fill in our knowledge of anger-pstd relationships in the french population and by comparing civilian and military population.


Eligibility criteria:
inclusion criteria: * to have a ptsd diagnosis * to be at least 18 years of age exclusion criteria: * to suffer from trauma-related physical condition (including traumatic brain injury)
eyelid crush for marginal eyelid surgery

Conditions: Eyelid Diseases

Summary: surgery involves eyelid margin asscocited with intraoperative bleeding. proper intra-operative homeostasis is essential for good intraoperative procedure and postoperative results.

baseline and postoperative full ophthalmic examination was done.procedure include all surgeries involving eyelid margin

Eligibility criteria:
inclusion criteria: * all surgeries involving eyelid margin exclusion criteria: * bleeding tendency

Keywords: eyelid margin hemostasis
a phase 1b proof-of-concept trial exploring the effects of fe 999322 and fe 999324 in adults with mild to moderate ulcerative colitis

Conditions: Ulcerative Colitis

Summary: to explore the safety of fe 999322 (microbiota suspension) and fe 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (uc).


Eligibility criteria:
inclusion criteria: * subject aged ≥18 at screening * established diagnosis of ulcerative colitis by standard clinical, endoscopic and histological criteria, for more than 3 months at screening exclusion criteria: * active disease or history of crohn's disease * active disease or history of irritable bowel syndrome (ibs) or any other chronic intestinal disease apart from uc * active gastrointestinal infection.
safety and efficacy dose of artesunate used in combination with lapdap treatment of uncomplicated falciparum malaria

Conditions: Malaria

Summary: drug resistance to a range of antimalarial treatments has become widespread in africa, south east asia and south america. because the rapid spread of drug resistance threatens a public health disaster in these areas of the world and to comply with the who-roll back malaria policy of using artemisinin-based combination therapies (act), there is a need to develop new, safe, effective and affordable act. chlorproguanil-dapsone-artesunate (cda)is a new act that is being developed for the treatment of uncomplicated falciparum malaria in africa.


Eligibility criteria:
inclusion criteria: * presentation to a healthcare facility with probable uncomplicated clinical malaria * adults aged between 18 and 60 years , or children aged between 12 and 120 months * weight between 5 and 85kg * pure \[on microscopic grounds\] screening p. falciparum parasitaemia in children from 25,000 to 100,000ul-1, or in adults from 10,000 to 100,000ul-1. \[the parasitaemia range for adults was originally set at 25,000 to 100,000µl-1 and changed to 10,000 to 100,000µl-1 in protocol amendment 3 dated 05 may 2004\] * written or oral witnessed consent obtained from subject, parent or guardian * compliance with the requirements of the protocol which include a hospital stay of 4 days and 3 nights and regular blood samples by finger-prick (children) or via a cannula (adults) * a negative pregnancy test for women of child-bearing age on enrolment exclusion criteria: * features of severe/complicated falciparum malaria * known allergy to sulphonamides * evidence of any concomitant infection at the time of presentation (including p. ovale and p. malaria) * any other underlying disease that would compromise the diagnosis and the evaluation of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis and bacterial infection) * treatment in the 28-days prior to screening with sulfadoxine/pyrimethamine (fansidar, celoxine), sulfalene/pyrimethamine (metakelfin), mefloquine-sulfadoxinepyrimethamine (fansimet), chloroquine\* (nivaquine); treatment in the 21-days prior to screening with mefloquine, or 7-days prior to screening with amodiaquine, halofantrine, quinine (full course), atovaquone - proguanil, artemisinins, co-artemether, tetracycline or clindamycin, or treatment for 5 half-lives prior to screening with drugs that have a potential anti-malarial activity (e.g. co-trimoxazole in the previous 60 hours) * use of an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to screening * previous participation in this study * a positive pregnancy test at enrolment, women of child-bearing age who do not take a pregnancy test or female subjects who are breast-feeding an infant for the duration of the study

Keywords: dose-ranging study sb-714703 artesunate, malaria cda, chlorproguanil, dapsone,
assessment of thermal condition of health workers who use personal protective equipment from biological hazards during their work with covid-19 patients

Conditions: Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients

Summary: this research will provide data on thermal condition of medical workers who use personal protective equipment from biological hazards. aquired data will be used to define acceptable period of use for these protective costumes. this research will recruit 6 volunteers. during 6 hours each subject will perform their work using protective costume. heart rate, skin and air temperature under costume and hygrometric data will be registered. also there will be questionnaires for volunteers for subjective assessment of thermal and moisture sensations.


Eligibility criteria:
inclusion criteria: * healthy individuals (based on medical screening) exclusion criteria: * endocrinological diseases and disorders * health deviations at the time of the study

Keywords: thermophysiology personal protective equipment from biological hazards medical workers covid-19
immunotherapy in eyelid viral papilloma

Conditions: Eye Infections

Summary: intralesional injection of candida antigens for treating eyelid warts is supposed to have less destructive effect than other surgical interventions

despite many surgical and interventional modalities of treating ocular warts, all have a destructive nature for this delicate tissue with a high recurrence rate. intralesional injection of candida antigens was suggested to be an effective and safe treatment for such a condition aim: providing safe and effective treatment of ocular wart. objective: 1. to determine the efficacy of intralesional injection of candida antigens in the treatment of eyelids wart 2. to determine the safety of intralesional injection of candida antigens in the treatment of eyelids wart 3. to report complications of intralesional injection of candida antigens in the treatment of eyelids wart

Eligibility criteria:
inclusion criteria: * patients with cutaneous eyelid viral warts whether single or multiple, with no concurrent systemic or topical treatment for warts. patients aged more than 12 years, with sensitivity test, showed induration less than or equal to five mm. and patients can understand and comply with the requirements of the trials. exclusion criteria: * pregnancy, breastfeeding, patients with immunodeficiency; like diabetics. in addition, patients with a history of hypersensitivity to any used component in this trial, asthma, or allergic skin diseases. moreover, patients on any treatment modality for warts at least 1 month before the start of the study.

Keywords: eyelid warts, candida antigen, eyelid papilloma
effect of dexamethasone as analgesic treatment after total knee arthroplasty

Conditions: Postoperative Pain

Summary: effect of dexamethasone as analgesic treatment after total knee arthroplasty: subgroup analyses of the dex-2-tka randomized clinical trial this explorative post-hoc analysis is a substudy of the dex-2-tka-trial (nct03506789) investigating diffefferent subgroups of the patients included in the main trial.

effect of dexamethasone as analgesic treatment after total knee arthroplasty: subgroup analyses of the dex-2-tka randomized clinical trial this explorative post-hoc analysis is a substudy of the dex-2-tka-trial (nct03506789) investigating diffefferent subgroups of the patients included in the main trial.

Eligibility criteria:
inclusion criteria: * participation in the dex-2-tka-trial